Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Artiva Biotherapeutics (Nasdaq: ARTV), a clinical-stage biotech company focused on developing cell therapies for autoimmune diseases and cancers, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.
The company's management will deliver a presentation on Monday, April 7, 2025, at 11:00 a.m. EDT. The management team will also be available for meetings with registered conference investors.
A live webcast of the presentation will be accessible to investors and the public through the 'Investors' section of Artivabio.com. The webcast recording will remain available for 90 days following the event.
Artiva Biotherapeutics (Nasdaq: ARTV), un'azienda biotech in fase clinica focalizzata sullo sviluppo di terapie cellulari per malattie autoimmuni e tumori, ha annunciato la sua partecipazione alla prossima 24a Conferenza Virtuale Annuale di Needham sulla Salute.
La direzione dell'azienda presenterà il proprio intervento lunedì 7 aprile 2025, alle 11:00 EDT. Il team dirigenziale sarà inoltre disponibile per incontri con gli investitori registrati alla conferenza.
Una trasmissione in diretta della presentazione sarà accessibile agli investitori e al pubblico attraverso la sezione 'Investitori' di Artivabio.com. La registrazione della trasmissione rimarrà disponibile per 90 giorni dopo l'evento.
Artiva Biotherapeutics (Nasdaq: ARTV), una empresa biotecnológica en etapa clínica centrada en el desarrollo de terapias celulares para enfermedades autoinmunes y cánceres, ha anunciado su participación en la próxima 24ª Conferencia Virtual Anual de Salud de Needham.
La dirección de la empresa realizará una presentación el lunes 7 de abril de 2025, a las 11:00 a.m. EDT. El equipo de gestión también estará disponible para reuniones con los inversores registrados en la conferencia.
Una transmisión en vivo de la presentación estará accesible para inversores y el público a través de la sección 'Inversores' de Artivabio.com. La grabación de la transmisión permanecerá disponible durante 90 días después del evento.
Artiva Biotherapeutics (Nasdaq: ARTV), 자가면역 질환 및 암을 위한 세포 치료제를 개발하는 임상 단계의 생명공학 회사가 다가오는 제24회 니드햄 가상 의료 회의에 참여한다고 발표했습니다.
회사의 경영진은 2025년 4월 7일 월요일 오전 11:00 EDT에 발표를 진행할 예정입니다. 경영팀은 또한 등록된 회의 투자자들과의 미팅을 위해 대기할 것입니다.
발표의 라이브 웹캐스트는 투자자와 대중이 Artivabio.com의 '투자자' 섹션을 통해 접근할 수 있습니다. 웹캐스트 녹화는 이벤트 후 90일 동안 이용 가능합니다.
Artiva Biotherapeutics (Nasdaq: ARTV), une entreprise biopharmaceutique en phase clinique spécialisée dans le développement de thérapies cellulaires pour les maladies auto-immunes et les cancers, a annoncé sa participation à la prochaine 24e Conférence Virtuelle Annuelle de Needham sur la Santé.
La direction de l'entreprise fera une présentation le lundi 7 avril 2025, à 11h00 EDT. L'équipe de direction sera également disponible pour des réunions avec les investisseurs inscrits à la conférence.
Un webinaire en direct de la présentation sera accessible aux investisseurs et au public via la section 'Investisseurs' de Artivabio.com. L'enregistrement du webinaire restera disponible pendant 90 jours après l'événement.
Artiva Biotherapeutics (Nasdaq: ARTV), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Zelltherapien für Autoimmunerkrankungen und Krebs konzentriert, hat seine Teilnahme an der bevorstehenden 24. jährlichen virtuellen Gesundheitskonferenz von Needham angekündigt.
Das Management des Unternehmens wird am Montag, den 7. April 2025, um 11:00 Uhr EDT eine Präsentation halten. Das Managementteam wird auch für Meetings mit registrierten Konferenzinvestoren zur Verfügung stehen.
Ein Live-Webcast der Präsentation wird für Investoren und die Öffentlichkeit über den Bereich 'Investoren' auf Artivabio.com zugänglich sein. Die Aufzeichnung des Webcasts bleibt 90 Tage nach der Veranstaltung verfügbar.
- None.
- None.
SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 11:00 a.m. EDT.
Members of the Artiva management team will also be available to participate in investor meetings with investors who are registered to attend the conference.
Investors and the general public are invited to listen to a live webcast of the presentation through the "Investors" section on Artivabio.com. A webcast replay will be made available following the event for 90 days.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK®, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK® is currently in clinical trials for treatment of systemic lupus erythematosus, for patients with or without lupus nephritis, and in an investigator-initiated basket trial in multiple autoimmune indications. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs. Artiva is headquartered in San Diego, California.
For more information, please visit https://www.artivabio.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding upcoming events or Artiva Biotherapeutics, Inc.’s (the “Company”) participation at such events. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investors: Neha Krishnamohan, Artiva Biotherapeutics, ir@artivabio.com
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com,
+1.858.344.8091
Source: Artiva Biotherapeutics, Inc.
FAQ
When is Artiva Biotherapeutics (ARTV) presenting at the Needham Healthcare Conference 2025?
How can investors watch Artiva's (ARTV) Needham Conference presentation?
What type of therapies is Artiva Biotherapeutics (ARTV) developing?
Will Artiva (ARTV) management be available for investor meetings at the Needham Conference?
